

Ascelia Pharma - All attention on the top priority

Ascelias priority is to secure a re-reader evaluation of SPARKLE by May 2024. This involves minimising the risk of excessive intra reader variability. The time table is realistic but the risk for delays are never zero. Our base case is now a US partner strategy which could bring several advantages in our view. Our update includes a base case valuation of SEK 10 (11) and a Bull Case of SEK 26 (28), and a Bear Case of SEK 3 (3).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ascelia Pharma - All attention on the top priority